Guides
Is Tirzepatide Legal? What the FDA Actually Says in 2026
Tirzepatide is FDA-approved as Mounjaro and Zepbound — but 'compounded tirzepatide' is a different, much narrower legal story. Current FDA status with primary sources, and the red flags to check.
Tirzepatide is the odd one out among the substances we cover in this glossary. BPC-157, ipamorelin and sermorelin raise the question “does the FDA allow this at all?” Tirzepatide doesn’t — it is an approved drug. The real question is which version of it a clinic is selling you, and on what legal basis.
What it is
Tirzepatide is a once-weekly injectable that activates two receptors, GIP and GLP-1. It is a prescription drug. It is not a supplement and not a “research peptide.”
The FDA status, in order
Approved, under two brand names. We queried FDA’s Drugs@FDA data through the public openFDA API on October 2, 2026. Tirzepatide appears under two applications, both from Eli Lilly: NDA 215866 (Mounjaro, original approval record dated May 13, 2022) and NDA 217806 (Zepbound, original approval record dated November 8, 2023). Both are marketed as prescription subcutaneous injections. We also checked DailyMed, the National Library of Medicine’s labeling database: it returns 8 tirzepatide labels, all Mounjaro or Zepbound (including repackager listings).
Not on the compounding bulks list. Section 503A of the FD&C Act lets state-licensed pharmacies compound from a bulk substance if it meets certain criteria. We checked FDA’s 503A Bulk Drug Substances page (last modified May 14, 2026) and found no mention of tirzepatide. We also found none on FDA’s Category 2 safety-risk page (last modified April 22, 2026). That is not a “ban,” but it means that compounding from raw tirzepatide has no listed basis under the bulks pathway.
FDA’s current position on unapproved versions. FDA’s page “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” (content modified October 1, 2026) states that compounded drugs “should only be used in patients whose medical needs cannot be met by an FDA-approved drug.” It also warns about fraudulent compounded tirzepatide with false label information — in some cases naming a licensed pharmacy that, according to FDA, did not compound the product — and cites one reported adverse event tied to a product labeled as compounded tirzepatide from a pharmacy that did not actually make it. Separately, FDA reports adverse events, some requiring hospitalization, possibly related to dosing errors with compounded GLP-1 products, including doses above the approved label or faster titration.
What we did not re-verify today. The drug-shortage status that once opened a wider compounding window is covered, with its FDA source, in our brand-vs-compounded guide. FDA’s tirzepatide shortage page returned HTTP 404 when we tried it today, so we do not restate shortage dates here.
What this means for a clinic menu
If a clinic says “tirzepatide,” ask which of three things it means: brand-name Mounjaro or Zepbound dispensed from a pharmacy; a patient-specific compounded prescription with a documented clinical reason the brand product cannot meet; or something sold as “research” or “tirzepatide-like.” The first is plainly legal. The second sits in a narrow, FDA-scrutinized lane. The third is not a legal pathway.
Red flags we check for
A flat “tirzepatide program” with no sourcing detail. Brand or compounded? Which pharmacy? A clinic that can’t say is hiding the answer that matters.
Claims that compounded is “the same as” Zepbound. FDA lists this exact claim among its telehealth red flags.
Prices that look too good to be true, or product that arrives looking different from what you were told. Both are also on FDA’s list.
“For research use only” labels paired with human dosing instructions.
No named, NPI-verified prescriber. Same test we apply to every clinic in the directory.
See the verified clinics in Houston (currently 6 of the 22 clinics in our dataset carry the verified status; the rest are pending), then read how we verify.
Sources: FDA, Drugs@FDA via openFDA (api.fda.gov/drug/drugsfda.json, tirzepatide: NDA 215866 and NDA 217806), retrieved October 2, 2026. NLM DailyMed API (spls.json?drug_name=tirzepatide, 8 results), retrieved October 2, 2026. FDA, “Bulk Drug Substances Used in Compounding Under Section 503A”, modified May 14, 2026, retrieved October 2, 2026. FDA, “Certain Bulk Drug Substances … That May Present Significant Safety Risks”, modified April 22, 2026, retrieved October 2, 2026. FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”, modified October 1, 2026, retrieved October 2, 2026.
This article is independent editorial content, not medical advice. See our medical disclaimer.